ChabiotechLtd Balance Sheet Health
Financial Health criteria checks 4/6
ChabiotechLtd has a total shareholder equity of ₩705.5B and total debt of ₩445.6B, which brings its debt-to-equity ratio to 63.2%. Its total assets and total liabilities are ₩1,890.5B and ₩1,185.0B respectively.
Key information
63.2%
Debt to equity ratio
₩445.59b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩248.50b |
| Equity | ₩705.50b |
| Total liabilities | ₩1.18t |
| Total assets | ₩1.89t |
Recent financial health updates
Recent updates
Chabiotech Co.,Ltd.'s (KOSDAQ:085660) Shares Lagging The Industry But So Is The Business
Aug 07
Is CHA Biotech (KOSDAQ:085660) Using Too Much Debt?
Mar 01If You Had Bought CHA Biotech's (KOSDAQ:085660) Shares Three Years Ago You Would Be Down 52%
Jan 25The Trends At CHA Biotech (KOSDAQ:085660) That You Should Know About
Dec 21Financial Position Analysis
Short Term Liabilities: A085660's short term assets (₩605.4B) do not cover its short term liabilities (₩831.6B).
Long Term Liabilities: A085660's short term assets (₩605.4B) exceed its long term liabilities (₩353.4B).
Debt to Equity History and Analysis
Debt Level: A085660's net debt to equity ratio (27.9%) is considered satisfactory.
Reducing Debt: A085660's debt to equity ratio has increased from 31.8% to 63.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A085660 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A085660 has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 21% each year.